Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.18 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.18 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook, emphasizing the importance of long-term strategy over immediate financial results. They did not provide specific guidance, reflecting uncertainty in the market.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on long-term growth despite current challenges.
The earnings report indicates that Twist Bioscience is facing challenges, as reflected in the missed EPS figure. The stock reacted negatively, dropping 4.78%, likely due to the lack of revenue data and guidance. Investors may be concerned about the company's short-term performance and future prospects without clear direction from management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SEAGATE TECHNOLOGY H
Feb 4, 2019